MovDisordV3, PascalFrancis, Corpus, bibRecord, 001814

Regional metabolic changes in Parkinsonian patients with normal dopaminergic imaging

Identifieur interne : 001814 ( PascalFrancis/Corpus ); précédent : 001813; suivant : 001815

Regional metabolic changes in Parkinsonian patients with normal dopaminergic imaging

Auteurs : Thomas Eckert ; Andrew Feigin ; Daniel E. Lewis ; Vijay Dhawan ; Steven Frucht ; David Eidelberg

Source :

Movement disorders [ 0885-3185 ] ; 2007.

RBID : Pascal:07-0133238

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Parkinson maladie, Homme, Métabolisme, Tomoscintigraphie, Positon, Tomographie émission positon.

English descriptors

KwdEn :
- Emission tomography, Human, Metabolism, Nervous system diseases, Parkinson disease, Positron, Positron emission tomography.

Abstract

Dopaminergic imaging has been found to be normal in approximately 15% of parkinsonian patients enrolled in neuroprotective trials. We used ¹⁸F-fluorodeoxyglucose positron emission tomography (FDG PET) to determine the metabolic basis for this finding. We reviewed scans from 185 patients with clinical signs of Parkinson's disease (PD) who underwent ¹⁸F-fluorodopa PET imaging for diagnostic confirmation. Of this group, 27 patients (14.6%) had quantitatively normal scans; 8 of these patients were additionally scanned with FDG PET. Pattern analysis was performed on an individual scan basis to determine whether the metabolic changes were consistent with classic PD. Computer-assisted single-case assessments of the FDG PET scans of these 8 patients did not disclose patterns of regional metabolic change compatible with classical PD or an atypical parkinsonian variant. Similarly, network quantification revealed that PD-related pattern expression was not elevated in these patients as it was in an age- and duration-matched cohort with classical PD (P < 0.0001). None of these patients developed clinical signs of classical PD or of an atypical parkinsonian syndrome at a follow-up visit conducted 3 years after imaging. The results suggest that parkinsonian subjects with normal dopaminergic imaging do not have evidence of classical PD or an atypical parkinsonian syndrome.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 22`
A06				`@2 2`
A08	`01`	`1`	`ENG`	`@1 Regional metabolic changes in Parkinsonian patients with normal dopaminergic imaging`
A11	`01`	`1`		`@1 ECKERT (Thomas)`
A11	`02`	`1`		`@1 FEIGIN (Andrew)`
A11	`03`	`1`		`@1 LEWIS (Daniel E.)`
A11	`04`	`1`		`@1 DHAWAN (Vijay)`
A11	`05`	`1`		`@1 FRUCHT (Steven)`
A11	`06`	`1`		`@1 EIDELBERG (David)`
A14	`01`			`@1 Center for Neurosciences, Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System @2 Manhasset, New York @3 USA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 6 aut.`
A14	`02`			`@1 Department of Neurology II, University of Magdeburg @3 DEU @Z 1 aut.`
A14	`03`			`@1 Department of Neurology and Medicine, North Shore University Hospital and New York University School of Medicine @2 New York, New York @3 USA @Z 2 aut. @Z 4 aut. @Z 6 aut.`
A14	`04`			`@1 The Neurological Institute, Columbia-Presbyterian Medical Center @2 New York, New York @3 USA @Z 5 aut.`
A20				`@1 167-173`
A21				`@1 2007`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000145528070030`
A44				`@0 0000 @1 © 2007 INIST-CNRS. All rights reserved.`
A45				`@0 23 ref.`
A47	`01`	`1`		`@0 07-0133238`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Dopaminergic imaging has been found to be normal in approximately 15% of parkinsonian patients enrolled in neuroprotective trials. We used ¹⁸F-fluorodeoxyglucose positron emission tomography (FDG PET) to determine the metabolic basis for this finding. We reviewed scans from 185 patients with clinical signs of Parkinson's disease (PD) who underwent ¹⁸F-fluorodopa PET imaging for diagnostic confirmation. Of this group, 27 patients (14.6%) had quantitatively normal scans; 8 of these patients were additionally scanned with FDG PET. Pattern analysis was performed on an individual scan basis to determine whether the metabolic changes were consistent with classic PD. Computer-assisted single-case assessments of the FDG PET scans of these 8 patients did not disclose patterns of regional metabolic change compatible with classical PD or an atypical parkinsonian variant. Similarly, network quantification revealed that PD-related pattern expression was not elevated in these patients as it was in an age- and duration-matched cohort with classical PD (P < 0.0001). None of these patients developed clinical signs of classical PD or of an atypical parkinsonian syndrome at a follow-up visit conducted 3 years after imaging. The results suggest that parkinsonian subjects with normal dopaminergic imaging do not have evidence of classical PD or an atypical parkinsonian syndrome.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B24A06`
C02	`03`	`X`		`@0 002B17F`
C03	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 01`
C03	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 01`
C03	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 01`
C03	`02`	`X`	`FRE`	`@0 Parkinson maladie @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinson disease @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson enfermedad @5 02`
C03	`03`	`X`	`FRE`	`@0 Homme @5 09`
C03	`03`	`X`	`ENG`	`@0 Human @5 09`
C03	`03`	`X`	`SPA`	`@0 Hombre @5 09`
C03	`04`	`X`	`FRE`	`@0 Métabolisme @5 10`
C03	`04`	`X`	`ENG`	`@0 Metabolism @5 10`
C03	`04`	`X`	`SPA`	`@0 Metabolismo @5 10`
C03	`05`	`X`	`FRE`	`@0 Tomoscintigraphie @5 11`
C03	`05`	`X`	`ENG`	`@0 Emission tomography @5 11`
C03	`05`	`X`	`SPA`	`@0 Tomocentelleografía @5 11`
C03	`06`	`X`	`FRE`	`@0 Positon @5 12`
C03	`06`	`X`	`ENG`	`@0 Positron @5 12`
C03	`06`	`X`	`SPA`	`@0 Positrón @5 12`
C03	`07`	`X`	`FRE`	`@0 Tomographie émission positon @5 13`
C03	`07`	`X`	`ENG`	`@0 Positron emission tomography @5 13`
C03	`07`	`X`	`SPA`	`@0 Tomografía emisión positrones @5 13`
C07	`01`	`X`	`FRE`	`@0 Encéphale pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
N21				`@1 085`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 07-0133238 INIST
ET :	Regional metabolic changes in Parkinsonian patients with normal dopaminergic imaging
AU :	ECKERT (Thomas); FEIGIN (Andrew); LEWIS (Daniel E.); DHAWAN (Vijay); FRUCHT (Steven); EIDELBERG (David)
AF :	Center for Neurosciences, Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System/Manhasset, New York/Etats-Unis (1 aut., 2 aut., 3 aut., 4 aut., 6 aut.); Department of Neurology II, University of Magdeburg/Allemagne (1 aut.); Department of Neurology and Medicine, North Shore University Hospital and New York University School of Medicine/New York, New York/Etats-Unis (2 aut., 4 aut., 6 aut.); The Neurological Institute, Columbia-Presbyterian Medical Center/New York, New York/Etats-Unis (5 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2007; Vol. 22; No. 2; Pp. 167-173; Bibl. 23 ref.
LA :	Anglais
EA :	Dopaminergic imaging has been found to be normal in approximately 15% of parkinsonian patients enrolled in neuroprotective trials. We used ¹⁸F-fluorodeoxyglucose positron emission tomography (FDG PET) to determine the metabolic basis for this finding. We reviewed scans from 185 patients with clinical signs of Parkinson's disease (PD) who underwent ¹⁸F-fluorodopa PET imaging for diagnostic confirmation. Of this group, 27 patients (14.6%) had quantitatively normal scans; 8 of these patients were additionally scanned with FDG PET. Pattern analysis was performed on an individual scan basis to determine whether the metabolic changes were consistent with classic PD. Computer-assisted single-case assessments of the FDG PET scans of these 8 patients did not disclose patterns of regional metabolic change compatible with classical PD or an atypical parkinsonian variant. Similarly, network quantification revealed that PD-related pattern expression was not elevated in these patients as it was in an age- and duration-matched cohort with classical PD (P < 0.0001). None of these patients developed clinical signs of classical PD or of an atypical parkinsonian syndrome at a follow-up visit conducted 3 years after imaging. The results suggest that parkinsonian subjects with normal dopaminergic imaging do not have evidence of classical PD or an atypical parkinsonian syndrome.
CC :	002B17; 002B24A06; 002B17F
FD :	Système nerveux pathologie; Parkinson maladie; Homme; Métabolisme; Tomoscintigraphie; Positon; Tomographie émission positon
FG :	Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie
ED :	Nervous system diseases; Parkinson disease; Human; Metabolism; Emission tomography; Positron; Positron emission tomography
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease
SD :	Sistema nervioso patología; Parkinson enfermedad; Hombre; Metabolismo; Tomocentelleografía; Positrón; Tomografía emisión positrones
LO :	INIST-20953.354000145528070030
ID :	07-0133238

Links to Exploration step

Pascal:07-0133238

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Regional metabolic changes in Parkinsonian patients with normal dopaminergic imaging</title>
<author><name sortKey="Eckert, Thomas" sort="Eckert, Thomas" uniqKey="Eckert T" first="Thomas" last="Eckert">Thomas Eckert</name>
<affiliation><inist:fA14 i1="01"><s1>Center for Neurosciences, Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System</s1>
<s2>Manhasset, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology II, University of Magdeburg</s1>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Feigin, Andrew" sort="Feigin, Andrew" uniqKey="Feigin A" first="Andrew" last="Feigin">Andrew Feigin</name>
<affiliation><inist:fA14 i1="01"><s1>Center for Neurosciences, Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System</s1>
<s2>Manhasset, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology and Medicine, North Shore University Hospital and New York University School of Medicine</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lewis, Daniel E" sort="Lewis, Daniel E" uniqKey="Lewis D" first="Daniel E." last="Lewis">Daniel E. Lewis</name>
<affiliation><inist:fA14 i1="01"><s1>Center for Neurosciences, Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System</s1>
<s2>Manhasset, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dhawan, Vijay" sort="Dhawan, Vijay" uniqKey="Dhawan V" first="Vijay" last="Dhawan">Vijay Dhawan</name>
<affiliation><inist:fA14 i1="01"><s1>Center for Neurosciences, Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System</s1>
<s2>Manhasset, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology and Medicine, North Shore University Hospital and New York University School of Medicine</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Frucht, Steven" sort="Frucht, Steven" uniqKey="Frucht S" first="Steven" last="Frucht">Steven Frucht</name>
<affiliation><inist:fA14 i1="04"><s1>The Neurological Institute, Columbia-Presbyterian Medical Center</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Eidelberg, David" sort="Eidelberg, David" uniqKey="Eidelberg D" first="David" last="Eidelberg">David Eidelberg</name>
<affiliation><inist:fA14 i1="01"><s1>Center for Neurosciences, Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System</s1>
<s2>Manhasset, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology and Medicine, North Shore University Hospital and New York University School of Medicine</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">07-0133238</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 07-0133238 INIST</idno>
<idno type="RBID">Pascal:07-0133238</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001814</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Regional metabolic changes in Parkinsonian patients with normal dopaminergic imaging</title>
<author><name sortKey="Eckert, Thomas" sort="Eckert, Thomas" uniqKey="Eckert T" first="Thomas" last="Eckert">Thomas Eckert</name>
<affiliation><inist:fA14 i1="01"><s1>Center for Neurosciences, Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System</s1>
<s2>Manhasset, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology II, University of Magdeburg</s1>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Feigin, Andrew" sort="Feigin, Andrew" uniqKey="Feigin A" first="Andrew" last="Feigin">Andrew Feigin</name>
<affiliation><inist:fA14 i1="01"><s1>Center for Neurosciences, Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System</s1>
<s2>Manhasset, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology and Medicine, North Shore University Hospital and New York University School of Medicine</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lewis, Daniel E" sort="Lewis, Daniel E" uniqKey="Lewis D" first="Daniel E." last="Lewis">Daniel E. Lewis</name>
<affiliation><inist:fA14 i1="01"><s1>Center for Neurosciences, Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System</s1>
<s2>Manhasset, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dhawan, Vijay" sort="Dhawan, Vijay" uniqKey="Dhawan V" first="Vijay" last="Dhawan">Vijay Dhawan</name>
<affiliation><inist:fA14 i1="01"><s1>Center for Neurosciences, Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System</s1>
<s2>Manhasset, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology and Medicine, North Shore University Hospital and New York University School of Medicine</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Frucht, Steven" sort="Frucht, Steven" uniqKey="Frucht S" first="Steven" last="Frucht">Steven Frucht</name>
<affiliation><inist:fA14 i1="04"><s1>The Neurological Institute, Columbia-Presbyterian Medical Center</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Eidelberg, David" sort="Eidelberg, David" uniqKey="Eidelberg D" first="David" last="Eidelberg">David Eidelberg</name>
<affiliation><inist:fA14 i1="01"><s1>Center for Neurosciences, Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System</s1>
<s2>Manhasset, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology and Medicine, North Shore University Hospital and New York University School of Medicine</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Emission tomography</term>
<term>Human</term>
<term>Metabolism</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Positron</term>
<term>Positron emission tomography</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Parkinson maladie</term>
<term>Homme</term>
<term>Métabolisme</term>
<term>Tomoscintigraphie</term>
<term>Positon</term>
<term>Tomographie émission positon</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Dopaminergic imaging has been found to be normal in approximately 15% of parkinsonian patients enrolled in neuroprotective trials. We used <sup>18</sup>
F-fluorodeoxyglucose positron emission tomography (FDG PET) to determine the metabolic basis for this finding. We reviewed scans from 185 patients with clinical signs of Parkinson's disease (PD) who underwent <sup>18</sup>
F-fluorodopa PET imaging for diagnostic confirmation. Of this group, 27 patients (14.6%) had quantitatively normal scans; 8 of these patients were additionally scanned with FDG PET. Pattern analysis was performed on an individual scan basis to determine whether the metabolic changes were consistent with classic PD. Computer-assisted single-case assessments of the FDG PET scans of these 8 patients did not disclose patterns of regional metabolic change compatible with classical PD or an atypical parkinsonian variant. Similarly, network quantification revealed that PD-related pattern expression was not elevated in these patients as it was in an age- and duration-matched cohort with classical PD (P < 0.0001). None of these patients developed clinical signs of classical PD or of an atypical parkinsonian syndrome at a follow-up visit conducted 3 years after imaging. The results suggest that parkinsonian subjects with normal dopaminergic imaging do not have evidence of classical PD or an atypical parkinsonian syndrome.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>22</s2>
</fA05>
<fA06><s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Regional metabolic changes in Parkinsonian patients with normal dopaminergic imaging</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>ECKERT (Thomas)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>FEIGIN (Andrew)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>LEWIS (Daniel E.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>DHAWAN (Vijay)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>FRUCHT (Steven)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>EIDELBERG (David)</s1>
</fA11>
<fA14 i1="01"><s1>Center for Neurosciences, Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System</s1>
<s2>Manhasset, New York</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Neurology II, University of Magdeburg</s1>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Neurology and Medicine, North Shore University Hospital and New York University School of Medicine</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>The Neurological Institute, Columbia-Presbyterian Medical Center</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA20><s1>167-173</s1>
</fA20>
<fA21><s1>2007</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000145528070030</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2007 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>23 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>07-0133238</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Dopaminergic imaging has been found to be normal in approximately 15% of parkinsonian patients enrolled in neuroprotective trials. We used <sup>18</sup>
F-fluorodeoxyglucose positron emission tomography (FDG PET) to determine the metabolic basis for this finding. We reviewed scans from 185 patients with clinical signs of Parkinson's disease (PD) who underwent <sup>18</sup>
F-fluorodopa PET imaging for diagnostic confirmation. Of this group, 27 patients (14.6%) had quantitatively normal scans; 8 of these patients were additionally scanned with FDG PET. Pattern analysis was performed on an individual scan basis to determine whether the metabolic changes were consistent with classic PD. Computer-assisted single-case assessments of the FDG PET scans of these 8 patients did not disclose patterns of regional metabolic change compatible with classical PD or an atypical parkinsonian variant. Similarly, network quantification revealed that PD-related pattern expression was not elevated in these patients as it was in an age- and duration-matched cohort with classical PD (P < 0.0001). None of these patients developed clinical signs of classical PD or of an atypical parkinsonian syndrome at a follow-up visit conducted 3 years after imaging. The results suggest that parkinsonian subjects with normal dopaminergic imaging do not have evidence of classical PD or an atypical parkinsonian syndrome.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B24A06</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17F</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Homme</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Human</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Hombre</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Métabolisme</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Metabolism</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Metabolismo</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Tomoscintigraphie</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Emission tomography</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Tomocentelleografía</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Positon</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Positron</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Positrón</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Tomographie émission positon</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Positron emission tomography</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Tomografía emisión positrones</s0>
<s5>13</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>085</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 07-0133238 INIST</NO>
<ET>Regional metabolic changes in Parkinsonian patients with normal dopaminergic imaging</ET>
<AU>ECKERT (Thomas); FEIGIN (Andrew); LEWIS (Daniel E.); DHAWAN (Vijay); FRUCHT (Steven); EIDELBERG (David)</AU>
<AF>Center for Neurosciences, Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System/Manhasset, New York/Etats-Unis (1 aut., 2 aut., 3 aut., 4 aut., 6 aut.); Department of Neurology II, University of Magdeburg/Allemagne (1 aut.); Department of Neurology and Medicine, North Shore University Hospital and New York University School of Medicine/New York, New York/Etats-Unis (2 aut., 4 aut., 6 aut.); The Neurological Institute, Columbia-Presbyterian Medical Center/New York, New York/Etats-Unis (5 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2007; Vol. 22; No. 2; Pp. 167-173; Bibl. 23 ref.</SO>
<LA>Anglais</LA>
<EA>Dopaminergic imaging has been found to be normal in approximately 15% of parkinsonian patients enrolled in neuroprotective trials. We used <sup>18</sup>
F-fluorodeoxyglucose positron emission tomography (FDG PET) to determine the metabolic basis for this finding. We reviewed scans from 185 patients with clinical signs of Parkinson's disease (PD) who underwent <sup>18</sup>
F-fluorodopa PET imaging for diagnostic confirmation. Of this group, 27 patients (14.6%) had quantitatively normal scans; 8 of these patients were additionally scanned with FDG PET. Pattern analysis was performed on an individual scan basis to determine whether the metabolic changes were consistent with classic PD. Computer-assisted single-case assessments of the FDG PET scans of these 8 patients did not disclose patterns of regional metabolic change compatible with classical PD or an atypical parkinsonian variant. Similarly, network quantification revealed that PD-related pattern expression was not elevated in these patients as it was in an age- and duration-matched cohort with classical PD (P < 0.0001). None of these patients developed clinical signs of classical PD or of an atypical parkinsonian syndrome at a follow-up visit conducted 3 years after imaging. The results suggest that parkinsonian subjects with normal dopaminergic imaging do not have evidence of classical PD or an atypical parkinsonian syndrome.</EA>
<CC>002B17; 002B24A06; 002B17F</CC>
<FD>Système nerveux pathologie; Parkinson maladie; Homme; Métabolisme; Tomoscintigraphie; Positon; Tomographie émission positon</FD>
<FG>Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie</FG>
<ED>Nervous system diseases; Parkinson disease; Human; Metabolism; Emission tomography; Positron; Positron emission tomography</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Sistema nervioso patología; Parkinson enfermedad; Hombre; Metabolismo; Tomocentelleografía; Positrón; Tomografía emisión positrones</SD>
<LO>INIST-20953.354000145528070030</LO>
<ID>07-0133238</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001814 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001814 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:07-0133238
   |texte=   Regional metabolic changes in Parkinsonian patients with normal dopaminergic imaging
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Regional metabolic changes in Parkinsonian patients with normal dopaminergic imaging

Regional metabolic changes in Parkinsonian patients with normal dopaminergic imaging

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri